Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 23 Apr 2023
The treatment of chronic thromboembolic pulmonary hypertension with balloon pulmonary angioplasty has an evolving safety profile over the years, from 2013 to 2022, as revealed by an analysis of more than two dozen studies.
Read Full NewsShroff emphasizes the need to address more than just liver health in patients with alcohol-associated liver disease and reviews trends in AUD pharmacotherapy prescriptions.
With regard to safety, there were no serious adverse events (AEs) or AEs of special interest deemed related to OCU410ST reported in the study.
Specifically, the alignment relates to a separate, planned clinical trial referred to as ASPIRE.
1.
Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.
2.
Coffee and tea linked to lower head and neck cancer risk
3.
Research has shown that Ga-68 FAPI PET enhances pancreatic cancer detection and staging.
4.
Approval in Endometrial Cancer Expanded; Masks at Cancer Centers; NPR Reporter Dies
5.
Breast Cancer Incidence Increased Due to Particulate Air Pollution, According to NIH Study.
1.
The Risk Factors of Venous Thromboembolism and How to Lower Your Chances
2.
Cardio-Oncology: Managing Heart Failure in Survivors of Cancer
3.
IGSF8: A Rising Star in Cancer Immunotherapy - Harnessing the Innate Immune System
4.
Uncovering the Subtle Signs of Prostate Cancer: Early Detection is Key
5.
Immuno-Oncology in Daily Practice: Transforming Cancer Care One Patient at a Time
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
2.
Navigating the Complexities of Ph Negative ALL - Part IX
3.
Exploring the Hospitalization Burden in Refractory and Relapsed ALL
4.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge